Document Detail


Long-term effects of simvastatin in hypercholesterolemic patients with NIDDM and additional atherosclerotic risk factors. Hyogo Simvastatin Study Group.
MedLine Citation:
PMID:  7642176     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Effects of 12 months of simvastatin treatment were examined in 48 NIDDM patients with total serum cholesterol levels exceeding 220 mg/dl and were compared with those in 35 nondiabetic patients with hypercholesterolemia. In the diabetic group, 5-10 mg of simvastatin given once daily at bedtime significantly lowered total cholesterol (21%). LDL cholesterol (28%), apoB (15%) and triglycerides (8%) levels. These changes were identical to those in the nondiabetic group, except for triglycerides which did not change significantly. HDL cholesterol increased significantly in the nondiabetic group but not in the diabetic group. The reductions in LDL cholesterol and apoB in hypercholesterolemic patients with NIDDM were not influenced by gender, age, glycemic control, the presence or absence of systemic hypertension, obesity and overt proteinuria. In addition, the decrease in LDL cholesterol was not affected by the number of risk factors per patient. Simvastatin did not significantly alter hemoglobin A1c or fasting plasma glucose and was well tolerated in both groups. Simvastatin produced beneficial effects on serum lipids and apolipoproteins and neutral effects on glycemic control in hypercholesterolemic patients with NIDDM, whether or not they had an additional atherosclerotic risk factor.
Authors:
T Kazumi; G Yoshino; A Ohki; K Matsuba; T Ino; M Amano; M Kasuga
Related Documents :
16784936 - Coronary artery disease prognosis and c-reactive protein levels improve in proportion t...
8497456 - Ciprofibrate--a profile.
25424006 - Atomistic molecular dynamics simulation reveals the mechanism by which cetp penetrates ...
8031206 - Comparative effects of lovastatin and niacin in primary hypercholesterolemia. a prospec...
3226376 - The effects of prenatal alcohol exposure on odor associative learning in rats.
22591906 - Recommended dietary reference intakes, nutritional goals and dietary guidelines for fat...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme     Volume:  27     ISSN:  0018-5043     ISO Abbreviation:  Horm. Metab. Res.     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-09-21     Completed Date:  1995-09-21     Revised Date:  2009-02-19    
Medline Journal Info:
Nlm Unique ID:  0177722     Medline TA:  Horm Metab Res     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  239-43     Citation Subset:  IM    
Affiliation:
Department of Medicine, Hyogo Medical Center for Adults, Akashi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use*
Arteriosclerosis / etiology*
Diabetes Mellitus, Type 2 / drug therapy*
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Hypercholesterolemia / drug therapy*
Lovastatin / analogs & derivatives*,  therapeutic use
Male
Middle Aged
Prospective Studies
Risk Factors
Simvastatin
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 75330-75-5/Lovastatin; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin, but not estrogen, correlated with indexes of desaturase function in obese women.
Next Document:  Parathyroid hormone secretion and serum calcium concentration--a deterministic view of its regulatio...